Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease?
- 76 Downloads
Purpose of Review
Although the risk of sudden cardiac death is high in patients with end-stage renal disease (ESRD), it is not clear if such patients benefit from the implantable cardioverter defibrillator (ICD). This paper reviews data on the risk of sudden cardiac death in ESRD patients and examines data on outcomes of ICDs in such patients.
Data from observational studies suggest that primary prevention ICDs may lower the risk of mortality in patients with mild to moderate chronic kidney disease but not in patients with ESRD. Data on secondary prevention ICDs in the setting of ESRD suggest survival benefit in select patients. The subcutaneous ICD is a promising therapy in patients with ESRD, but more data are needed on its short- and long-term outcomes in these patients.
Future studies should examine the outcomes of transvenous and subcutaneous ICDs in patients with ESRD.
KeywordsSudden cardiac death Implantable cardioverter defibrillator End-stage renal disease
Compliance with Ethical Standards
Conflict of Interest
Drs Al-Khatib, Friedman, Hess, Pun, and Sanders declare no conflicts of interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med. 1996;335(26):1933–40. doi: 10.1056/NEJM199612263352601.CrossRefPubMedGoogle Scholar
- 2.A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337(22):1576–1583. doi: 10.1056/NEJM199711273372202.
- 3.Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med. 1999;341(25):1882–90. doi: 10.1056/NEJM199912163412503.CrossRefPubMedGoogle Scholar
- 4.Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs implantable defibrillator study. Cardiac arrest study Hamburg. Canadian implantable defibrillator study. Eur Heart J. 2000;21(24):2071–8. doi: 10.1053/euhj.2000.2476.CrossRefPubMedGoogle Scholar
- 8.Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation. 2013;127:e283–352. doi: 10.1016/j.jacc.2012.11.007.Google Scholar
- 10.National Institute of Diabetes and Digestive and Kidney Diseases: 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, Cardiovascular Special Studies, 2006.Google Scholar
- 14.Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the dialysis outcomes and practice patterns study. Clinical journal of the American Society of Nephrology: CJASN. 2012;7(5):765–74. doi: 10.2215/CJN.08850811.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Goldenberg I, Moss AJ, McNitt S, Zareba W, Andrews ML, Hall WJ, et al., Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am J Cardiol. 2006;98:485–90. doi: 10.1016/j.amjcard.2006.03.025.CrossRefPubMedGoogle Scholar
- 17.Pun PH, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, et al. Implantable cardioverter defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kid Dis. 2014;64:32–9. doi: 10.1053/j.ajkd.2013.12.009.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.• Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol. 2015;10:1119–27. doi: 10.2215/CJN.11121114. This study reported on the outcomes of ICDs in patients with chronic kidney disease; it showed that ICDs are associated with survival benefit in patients with stage 3 chronic kidney disease but not in patients with stage 4 chronic kidney disease CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Aggarwal A, Wang Y, Rumsfeld JS, Curtis JP, Heidenreich PA, National Cardiovascular Data Registry. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm. 2009;6:1565–71. doi: 10.1016/j.hrthm.2009.08.006.CrossRefPubMedGoogle Scholar
- 22.• Hess PL, Hellkamp AS, Peterson ED, Sanders GD, Al-Khalidi HR, Curtis LH, et al. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. Circ: Arrhythm Electrophysiol. 2014;7:793–9. doi: 10.1161/CIRCEP.114.001455. This study examined the risk of 1-year death after ICD placement among 21,226 patients with chronic kidney disease and 26,056 patients with no chronic kidney disease. It found that the risk of death after primary prevention ICD placement was proportional to the severity of chronic kidney disease. This study also identified factors associated with increased risk of death that could inform clinical decision making Google Scholar
- 23.•• Pun PH, Hellkamp AS, Sanders GD, Middleton JP, Hammill SC, Al-Khalidi H, et al. Primary prevention implantable cardioverter defibrillators in end stage kidney disease patients on dialysis: a matched cohort study. Nephrology Dialysis Transplantation. 2015;30:829–35. doi: 10.1093/ndt/gfu274. This is the only published comparative effectiveness analysis of primary prevention ICDs in patients with ESRD. It showed no survival benefit associated with ICDs. Although the sample size of 108 ESRD patients was relatively small, this study highlighted the importance of conducting similar studies in larger groups of ESRD patients CrossRefGoogle Scholar
- 24.Hickson LJ, Gooden JY, Le KY, Baddour LM, Friedman PA, Hayes DL, et al. Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients. Am J Kidney Dis. 2014;64(1):104–10. doi: 10.1053/j.ajkd.2013.11.018.CrossRefPubMedPubMedCentralGoogle Scholar